BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The BioCalendar - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:The BioCalendar
X-ORIGINAL-URL:https://thebiocalendar.com
X-WR-CALDESC:Events for The BioCalendar
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20270314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20271107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260331T110000
DTEND;TZID=America/Los_Angeles:20260331T120000
DTSTAMP:20260414T200320
CREATED:20260220T125345Z
LAST-MODIFIED:20260220T125345Z
UID:9947-1774954800-1774958400@thebiocalendar.com
SUMMARY:Digital Design Meets Proven Performance: The Future of Single-Use Assemblies
DESCRIPTION:In today’s fast-paced biopharma and CDMO environments\, single-use assembly design is about confidence in quality\, supply continuity\, and process performance. This webinar explores how Thermo Scientific™ Single-Use Assemblies are designed to help reduce risk\, support flexible manufacturing\, and help organizations meet production milestones and maintain momentum when time to market is crucial. \nAttendees will see how automation-driven tools – including the Kaon™ app and the online Single-Use Assembly Configurator\, simplify and standardize assembly design. By bringing a broad\, trusted portfolio of components into one intuitive digital experience\, these tools accelerate design decisions\, improve consistency\, and reduce the effort required to move from concept to execution. \nWe will highlight three core considerations that set Thermo Scientific Single-Use Assemblies apart and deliver tangible value in real-world bioprocessing operations: \n    ~ Film technology for durable\, consistent performance across 2D and 3D bioprocess containers\n    ~ Integration of LifeASSURE™ sterilizing grade filters that streamline qualification\n    ~ Protection of process integrity at critical connection points to reduce risks of leaks \nJoin this webinar to learn how a standardized\, automated configuration experience\, backed by proven Thermo Scientific technologies to help biopharma and CDMO teams move faster\, reduce risk\, and execute with confidence.
URL:https://thebiocalendar.com/event/digital-design-meets-proven-performance-the-future-of-single-use-assemblies/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/02/03-31-26-Thermo-LinkedIn-1280x720-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260331T110000
DTEND;TZID=America/Los_Angeles:20260331T120000
DTSTAMP:20260414T200320
CREATED:20260303T140956Z
LAST-MODIFIED:20260303T140956Z
UID:9983-1774954800-1774958400@thebiocalendar.com
SUMMARY:The Phase 2 Endpoint Dilemma: Bridging Subjective Scales and Objective Measures in Neurodegenerative Trials
DESCRIPTION:Phase 2 neurodegenerative trials are increasingly challenged by slow disease trajectories\, heterogeneous patient populations\, and blunt legacy endpoints that struggle to detect treatment-related change over typical study durations. Traditional scales such as ADAS-Cog and MDS-UPDRS\, while well-established\, often lack sensitivity in early disease\, are vulnerable to rater and practice effects\, and may insufficiently capture subtle but clinically meaningful benefits. \nThis webinar will examine when and how to move beyond single-scale approaches toward more informative composite strategies\, highlighting circumstances in which composites enhance signal detection versus when they introduce additional noise\, complexity\, and interpretability risk. We will explore practical frameworks for integrating functional\, cognitive\, and biomarker measures into coherent endpoint hierarchies that support both mechanistic insight and regulatory relevance. Finally\, we will discuss how real-world evidence and natural history data can be leveraged to select\, calibrate\, and power Phase 2 endpoints capable of detecting meaningful change within shorter trial timeframes\, improving go/no-go decision quality for emerging neurodegenerative therapies. \nKey Learning Objectives:\n– Evaluate the strengths and limitations of traditional subjective scales (e.g.\, ADAS-Cog\, MDS-UPDRS) in Phase 2 neurodegenerative trials and identify when alternative or composite strategies are warranted \n– Apply practical frameworks to integrate cognitive\, functional\, and biomarker endpoints into coherent\, regulator-ready hierarchies that enhance signal detection while minimizing interpretability risk \n– Leverage real-world evidence and natural history datasets to inform endpoint selection\, calibration\, and powering strategies that improve Phase 2 go/no-go decision-making
URL:https://thebiocalendar.com/event/the-phase-2-endpoint-dilemma-bridging-subjective-scales-and-objective-measures-in-neurodegenerative-trials/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/03/Untitled-design-59.png
END:VEVENT
END:VCALENDAR